Serina <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Secures $20 Million Convertible Note with Board Member Gregory H. Bailey to Fund Clinical Milestones
Serina Therapeutics Inc., a Delaware corporation, has entered into a significant financing agreement through an unsecured convertible note with Gregory H. Bailey, M.D., a member of the company's Board of Directors. The agreement, finalized on September 9, 2025, provides Serina Therapeutics access to an aggregate principal amount of up to $20 million. This financial arrangement is structured around the achievement of specific clinical and operational milestones, allowing the company to draw funds in five tranches. The convertible note, which can be converted into Serina common stock at a conversion price of $5.18 per share, aims to support the company's ongoing and future clinical studies, particularly the SER-252-1b registrational clinical study. This development underscores Serina's strategic efforts to bolster its financial resources to advance its research and development initiatives.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Serina Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001708599-25-000110), on September 15, 2025, and is solely responsible for the information contained therein.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。